United Bank Grows Stake in Johnson & Johnson $JNJ

United Bank boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 32.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,310 shares of the company's stock after purchasing an additional 3,031 shares during the quarter. United Bank's holdings in Johnson & Johnson were worth $1,880,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at $218,000. GAMMA Investing LLC increased its holdings in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after acquiring an additional 14,118 shares during the period. L.M. Kohn & Company increased its holdings in shares of Johnson & Johnson by 186.9% in the 1st quarter. L.M. Kohn & Company now owns 34,460 shares of the company's stock valued at $5,715,000 after acquiring an additional 22,449 shares during the period. Finally, Compass Ion Advisors LLC increased its holdings in shares of Johnson & Johnson by 6.0% in the 1st quarter. Compass Ion Advisors LLC now owns 14,556 shares of the company's stock valued at $2,414,000 after acquiring an additional 830 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on JNJ shares. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a "neutral" rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. HSBC lifted their price target on Johnson & Johnson from $210.00 to $215.00 and gave the company a "buy" rating in a report on Thursday. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday. Finally, Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $199.88.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 0.6%

Shares of JNJ stock opened at $193.27 on Monday. The stock's fifty day moving average price is $180.49 and its 200 day moving average price is $164.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.